CMS Entry id: 2710 | Channel: News landing page | Template: news/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

News

1 August 2018

Healthy Amplified launch new population health platform with CANTAB technology

Healthy Amplified are using CANTAB® technology to expand their population health platform offering to adults. 


28 June 2018

CANTAB technology selected for world’s largest dementia study

We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.

20 June 2018

New product to improve workplace mental health

We are very pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.

7 June 2018

Cambridge Cognition and University of Bristol in partnership to tackle growing mental health need

Mental and substance use disorders are now the leading cause of disability worldwide, resulting in 23% of all years lost with a global economic loss of a trillion US dollars every year1 which is why we are very pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.

31 May 2018

New client signs with Cognition Kit software

We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.

30 May 2018

CANTAB Research Grant 2018 - Results

The results of the 2018 CANTAB Research Grant are in! Once again we were overwhelmed by the quality of applications we received – which made it a tough job for our judging panel to narrow the research proposals down.

10 April 2018

CANTAB Recruit software to be used in two major Phase III drug trials

​We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.